|
|
Blood, 1 March 2004, Vol. 103, No. 5, pp. 1955-1960.
Prepublished online as a Blood First Edition Paper on November 6, 2003; DOI 10.1182/blood-2003-03-0937.
Submitted March 26, 2003
Accepted October 30, 2003
Unrelated bone marrow transplantation for non-Hodgkin's lymphoma: a study from the Japan Marrow Donor Program
Koji Izutsu*, Yoshinobu Kanda, Hitoshi Ohno, Hiroshi Sao, Hiroyasu Ogawa, Yasushi Miyazaki, Keisei Kawa, Yoshihisa Kodera, Shunichi Kato, Yasuo Morishima, and Hisamaru Hirai
Department of Cell Therapy & Transplantation Medicine, University of Tokyo, Tokyo, Japan
Department of Hematology & Oncology, Graduate School of Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Department of Hematology, Meitetsu Hospital, Nagoya, Japan
Department of Molecular Medicine, Osaka University Graduate School of Medicine, Suita, Japan
Department of Hematology, Molecular Medicine Unit, Nagasaki University School of Medicine, Nagasaki, Japan
Department of Pediatrics, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan
Department of Internal Medicine, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan
Department of Cell Transplantation & Regenerative Medicine, Tokai University School of Medicine, Isehara, Japan
Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan
* Corresponding author; email: izutsu-tky{at}umin.ac.jp.
There is little information available regarding the outcome of unrelated bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL). Therefore, we retrospectively analyzed the data of 124 patients who underwent unrelated BMT through the Japan Marrow Donor Program (JMDP) between July 1992 and August 2001. The overall survival (OS), progression-free survival (PFS), cumulative incidences of disease progression, and non-progression mortality at 3 years after BMT were 49.7%, 42.6%, 24.5%, and 32.9%, respectively, with a median follow-up duration of 565 days among survivors. The incidence of grade II-IV acute GVHD was 40.9%. Recipient age, previous history of autologous transplantation, and chemosensitivity at transplantation were independent prognostic factors for OS and PFS. The development of grade II-IV acute GVHD was associated with lower incidence of disease progression after transplantation, which suggested the existence of a graft-versus-lymphoma effect. Unrelated BMT should be considered as a treatment option for patients with high-risk NHL without an HLA-matched related donor.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
N. Schmitz, P. Dreger, B. Glass, and A. Sureda
Allogeneic transplantation in lymphoma: current status
Haematologica,
November 1, 2007;
92(11):
1533 - 1548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-W. Kim, T. E. Tanimoto, N. Hirabayashi, S. Goto, M. Kami, S. Yoshioka, T. Uchida, K. Kishi, Y. Tanaka, A. Kohno, et al.
Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan
Blood,
July 1, 2006;
108(1):
382 - 389.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Maris, B. M. Sandmaier, B. E. Storer, T. Chauncey, M. J. Stuart, R. T. Maziarz, E. Agura, A. A. Langston, M. Pulsipher, R. Storb, et al.
Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma
Blood,
December 1, 2004;
104(12):
3535 - 3542.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
